Research Progress of Ropeginterferon α-2b in Treatment of Myelo-proliferative Neoplasm——Review

VernacularTitle:Ropeginterferon α-2b治疗骨髓增殖性肿瘤的研究进展
Author: Ling-Rong TU ¹ ; Jian HUANG
Author Information

1. 浙江大学医学院附属第四医院血液内科,浙江义乌 322000
Publication Type:Journal Article
Keywords: myeloproliferative neoplasms; ropeginterferon α-2b; interferon-alpha; therapy
From: Journal of Experimental Hematology 2025;33(1):306-310
CountryChina
Language:Chinese
Abstract: Ropeginterferon α-2b(Ropeg),a novel,long-acting pegylated prolene alpha interferon,is the first interferon specifically approved for the treatment of patients with polycythemia vera(PV),and has been found in clinical trials and experience to induce hematologic remission,control disease-related symptoms,and reduce JAK2V617F allelic burden in patients with myeloproliferative neoplasms(MPNs).It has a lower incidence and severity of adverse drug reactions than pegylated interferon alpha and hydroxyurea and a longer dosing interval.Some patients with low-risk PV and myelofibrosis can benefit from it.This article reviews the latest progress of Ropeg in MPN.